MSD's third-quarter global revenue was US$18.085 billion, up 5% year on year; net profit was US$5,065 billion, down 12% year on year; adjusted earnings per share were US$2.49, compared to US$2.58 for the same period last year. Core products Keytruda and Keytruda Qlex had sales of US$8.601 billion, up 6% year on year; the pulmonary hypertension drug Winrevair had sales of US$694 million, up 93% year on year. The company raised its full-year revenue guidance to US$66.8 billion to US$67.3 billion and raised its full-year adjusted earnings per share guidance to US$2.77 to US$2.82.

MSD's third-quarter global revenue was US$18.085 billion, up 5% year on year; net profit was US$5,065 billion, down 12% year on year; adjusted earnings per share were US$2.49, compared to US$2.58 for the same period last year. Core products Keytruda and Keytruda Qlex had sales of US$8.601 billion, up 6% year on year; the pulmonary hypertension drug Winrevair had sales of US$694 million, up 93% year on year. The company raised its full-year revenue guidance to US$66.8 billion to US$67.3 billion and raised its full-year adjusted earnings per share guidance to US$2.77 to US$2.82.